th edition 30 nov & 1 dec 2016 - biofit 2020 › programme final bf2016_web.pdfpartnering events...

1

organised by with the support of in collaboration with

A 360°approach to source early

stage innovations in Life Sciences

30th Nov & 1st Dec 2016 5TH EDITION

PROGRAMME

LILLE, FRANCE

2

ABOUT BIOFIT 2016

30+ one-to-one meetings per participant over

2 days

11 conferences

and roundtable discussions

60 high-level

international speakers

800 licensing

opportunities

1,300 DELEGATES

900 ORGANISATIONS

6 HOSTED EVENTS

50% INTERNATIONAL

ACTORS

30+ COUNTRIES

REPRESENTED

100 EXHIBITORS

BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations

and for sourcing early stage innovations in the field of Life Sciences.

3

SUMMARYAbout the organisers .......................................................................................4

The Steering Committee ...............................................................................5

Partnering .................................................................................................................6

Who will you meet? .........................................................................................7

A genda ............................................................................................................... 10 Day 1 ..................................................................................................................... 10 Day 2 ......................................................................................................................12

C onferences and roundtable discussions ................15 PLENARY SESSION ........................................................................................15 TRACK 1 Best practices in collaborative research ....................................... 16 TRACK 2 Key issues in licensing and tech transfer ........................................ 18 TRACK 3 Funding early stage innovation .......................................................20

Hosted events ....................................................................................................22

TechnoMarket and Start-up Slams ..................................................28

Floor plan ..............................................................................................................30

Exhibitors’ list ......................................................................................................32

Partners & Sponsors .....................................................................................55

LILLE 2016 - FRANCE

4

ABOUT THE ORGANISERS

Eurasanté is a non-profit organisation engaged in technology transfer and business development of companies and start-ups in Life Sciences sectors in Northern France.The regional network includes near 1,000 organisations working in the field of Life Sciences, Nutrition and Healthcare. Eurasante assists French and foreign companies interested in developing their activities or setting-up a business in Northern France. Eurasante provides many services such as access to public aids, find offices, administrative formalities, recruitment assistance, market studies… It also promotes the Eurasante Bio-business Park, which already hosts 7 hospitals, 4 universities, 7 specialised schools and more than 160 companies. It benefits from an exceptional location at the heart of Europe (near Paris, London, Brussels…).

www.eurasante.com

The Nutrition Health Longevity (NHL) cluster exists to foster ambitious, joint research projects in the Nord-Pas de Calais region, with a view to making the region’s industries more competitive. The NHL cluster was certified as a Competitiveness Cluster by the French Government in July 2005 and aims to become one of the top three innovators in Europe in the field of health and nutrition, by fostering collaboration on innovative research projects in the fields of cardiovascular and metabolic diseases, age-related neurodegenerative diseases and nutrition.As a hub for new medical, scientific and industrial strategies, NHL cluster has become a key player in forging links between private and public research players in its specialist fields.

www.nhl-cluster.com

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimize any R&D development or business project in Europe, both in drug development and medical technologies. Located in Eastern region of France, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies interested in new projects and partnerships in Europe: to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or to set up and locate in Eastern region. Alsace BioValley has also agreements with Biowin (Wallonia), CQDM (Quebec), JBA (Japan Bioidustry Association), Biopro (Germany) and Basel Area (Switzerland). Alsace BioValley is also closed involved in Nextmed, a Medtech Campus project which aims to create, a few meters from the New Hospital of Strasbourg, an outstanding environment for innovative medical devices.

www.alsace-biovalley.com www.biovalley.com

With the support of

in collaboration With

www.conectus.fr/en

5

THE STEERING COMMITTEE

5

Nadine WEISSLINGER-DARMON medical director specialty products, clinical research & academic alliances,gsk – glaxosmithkline [fr]

Maria BOBADILLA senior director, extending innovation netWork, roche [ch]

Adrian CARTER corporate vice president and global head of discovery research coordination, boehringer ingelheim [de]

Sami CHTOUROU director of technology platforms and innovation, lfb [fr]

Isabelle DIEUZY-LABAYE former director, strategic alliances, zoetis [fr]

Guy HELIN ceo, syngulon [be]

Sarah HOLLAND bd&l business partner to general medicines and emerging markets business unit, sanofi [fr]

Florence DAL DEGAN r&d innovation sourcing director, novo nordisk [dk]

Stephan LENSKY chief operating and chief business office, epimab biotherapeutics [cn]

Sabrina LESAGE strategic alliances manager, pfizer [fr]

Frédéric SCAEROU director, scientific affairs oncology, ipsen innovation [fr]

PHARMAS, BIOTECHS

Christian POLICARDmember of the board, chairman of the business development sub-committee, france biotech [fr]

Claude-Alain CUDENNEC general director, afssi - french association of outsourcing and innovative companies [fr]

Marco FIORINI general secretary, aviesan - french national alliance for life sciences and health [fr]

Barbara FREISCHEM managing director, ebe - european biopharmaceutical enterprises [be]

Didier FROMMWEILER general manager, alsace biovalley [fr]

Sara NUNEZ-GARCIA principal, sofinnova partners [fr]

Emilie ROYERE director, eurobiomed [fr]

Cécile THEARD-JALLU partner attorney, de gaulle fleurance & associés [fr]

Etienne VERVAECKE general manager, eurasante & nhl cluster [fr]

ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMSACADEMIA, TTOs

Hervé ANSANAY operations director, satt axlr [fr]

Ivan BAINES chief operating officer, max planck institute of molecular cell biology and genetics [de]

Garold BREIT director business development initiative, city of charleston [usa]

Nicolas CARBONI president, satt conectus alsace [fr]

Jean-Luc CHAGNAUD healthcare business development manager & intellectual property manager, aquitaine science transfert [fr]

Matthieu FISICHELLA life sciences expert, satt nord [fr]

Esther LANGE industry liaison manager, ascenion [de]

6

5%

30%

20%

20%

15%10%

PROFESSIONAL SERVICES, CONSULTING AND LAW FIRMS

SEED AND SERIES A INVESTORS

PRECLINICAL CROs

EMERGING BIOTECH

COMPANIES

PHARMA & DIAGNOSTIC COMPANIES

TTOs, RESEARCH

INSTITUTIONS, ACADEMICS

PARTNERING48 hours to meet your future project partners, accelerate your innovation and get financed

IDENTIFYtoday’s innovative technologies and

licensing opportunities

BENEFITfrom a wide-range

of attendees (Pharmas - Biotechs - TTOs

Academics - Investors)

MEETthe most qualified actors in the Life Sciences field

DEVELOP new collaborations

and partnerships

Partnering at BioFIT is powered by

7

Pfizer, J&J, Sanofi, Roche, GSK, Novo Nordisk, Lilly, Bayer, Merck, Ipsen, Evotec, Lonza, Boehringer Ingelheim, Sofinnova Partners,

Kurma Partners, Max Planck Institute, AbbVie, Debiopharm, Mitsubishi Tanabe Pharma, Teva, LFB, Onxeo, Hybrigenics,

Nanobiotix, Ascenion, VIB, Fraunhofer, Isis Innovation, Fund+, Merck Ventures, V-Bio Ventures, European Investment Fund,

Medicxi, Novo Seeds…

WHO WILL YOU MEET? 1,300

key actors gathered

From 30+ countries around the world

INCLUDING:

Bulgaria

South Korea

Estonia

Hungary Iceland Norway

Ukraine

8

ACCESS A WORLD OF OPPORTUNITIESTHROUGH OUR LIFE SCIENCE PARTNERING EVENTS

ebdgroup.com

Upcoming events:

Biolatam® San Juan, Puerto Rico // November 29–30, 2016

Biotech ShowcaseTM San Francisco, CA // January 9–11, 2017

BIO-Europe Spring® Barcelona, Spain // March 20–22, 2017

ChinaBio® Partnering Forum Shunde, China // May 10–11, 2017

BioEquity Europe Paris, France // May 22–23, 2017

Cell & Gene ExchangeWashington, DC // May 22–23, 2017

BioPharm AmericaTM Boston, MA // September 26–27, 2017

BIO-Europe®

Berlin, Germany // November 6–8, 2017

9

GlaxoSmithKline is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer.

We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. Our commercial success depends on creating innovative new products and making these accessible to as many people as possible. By achieving this, we will be able to grow our business and provide benefits to patients, consumers, society, our employees and our shareholders.

Our headquarters are based in the UK, and we have a wide geographical

reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally.

Research is vitally important to the success of our business, and we spent just under £4 billion each year in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

As a science-led global healthcare company we have the opportunity to improve the health and well-being of millions of people around the world.

Through investment in R&D and infrastructure, and through collaboration with other organisms and academic institutions, we are innovating to address currently unmet health needs. We are improving access to our products, irrespective of where people live or their ability to pay, and we are working to control or eliminate diseases affecting the world’s most vulnerable people.

GSK, A key player in R&D

10

TRACK 1 Best practices

in collaborative research

TRACK 2 Key issues in licensing

and tech transfer

TRACK 3 Funding early

stage innovation

Presentation sessions and TechnoMarket

by Réseau SATT Partnering Hosted event8.00 am 9.30 am

REGISTRATION AND WELCOME REGISTRATION AND WELCOME9.30 am11.00 am

Committed to the VC business:

Why and how universities are involved in new venture funds?

Van Gogh 1&2 room

Licensing Opportunities & TechnoMarket

ONCOLOGY Van Gogh 3 room

8.00 am

One-

to-one meetings Lille Metropole area

IDEASummit

Matisse 3 room

11.00 am11.30 am COFFEE BREAK COFFEE BREAK BREAK11.30 am12.00 pm Keynote. Amphitheatre Pasteur New models required for academic, biotech and pharma collaborations12.00 pm 1.00 pm Plenary Session. Amphitheatre Pasteur Is Europe competitive enough in Life Sciences innovation?1.00 pm 2:30 pm LUNCH LUNCH lunch

Pharma Logistics Club

Clinical trials and biologic products transportation

Artois 2 room

One-to-one

meetings Lille Metropole area

LUNCH2.00 - 2.30 pm:

Le Panorama de l’industrie des sciences de la vie® en France par France Biotech

2.30 - 5.15 pm:

Workshop Content, finances and governance of public-private

collaborations around the world

Artois 1 room

2.30 pm4.00 pm What is the best

background for the CEO of an academic spin-off?

Matisse 1&2 room

How to create a European

seed capital market?Van Gogh 1&2room

Start-up SlamsVan Gogh 3 room

IDEASummit

Matisse 3 room

4.00 pm4.30 pm COFFEE BREAK COFFEE BREAK COFFEE BREAK4.30 pm5.15 pm Workshops

Could your innovations be protected efficiently

by tools other than patents?

-What about regulatory data protection, trade secret, blockchain &

smart contracts?Matisse 1&2 room

Licensing Opportunities and

TechnoMarket

Van Gogh 3 room

IDEASummit

Matisse 3 room5.15 pm6.15 pm

6.30 pm

How can experienced entrepreneurs become involved and support today’s life sciences

start-ups?Van Gogh 1&2 room

7.00 pm BIOPARTY BIOPARTY

DAY ONE Wednesday 30th November

10

CONFERENCES

11




and tech transfer


stage innovation


by Réseau SATT Partnering Hosted event8.00 am 9.30 am

REGISTRATION AND WELCOME REGISTRATION AND WELCOME9.30 am11.00 am

Committed to the VC business:

Why and how universities are involved in new venture funds?

Van Gogh 1&2 room

Licensing Opportunities & TechnoMarket

ONCOLOGY Van Gogh 3 room

8.00 am

One-

to-one meetings Lille Metropole area

IDEASummit

Matisse 3 room

11.00 am11.30 am COFFEE BREAK COFFEE BREAK BREAK11.30 am12.00 pm Keynote. Amphitheatre Pasteur New models required for academic, biotech and pharma collaborations12.00 pm 1.00 pm Plenary Session. Amphitheatre Pasteur Is Europe competitive enough in Life Sciences innovation?1.00 pm 2:30 pm LUNCH LUNCH lunch

Pharma Logistics Club

Clinical trials and biologic products transportation

Artois 2 room

One-to-one


LUNCH2.00 - 2.30 pm:

Le Panorama de l’industrie des sciences de la vie® en France par France Biotech

2.30 - 5.15 pm:

Workshop Content, finances and governance of public-private

collaborations around the world

Artois 1 room

2.30 pm4.00 pm What is the best

background for the CEO of an academic spin-off?

Matisse 1&2 room

How to create a European

seed capital market?Van Gogh 1&2room

Start-up SlamsVan Gogh 3 room

IDEASummit

Matisse 3 room

4.00 pm4.30 pm COFFEE BREAK COFFEE BREAK COFFEE BREAK4.30 pm5.15 pm Workshops

Could your innovations be protected efficiently

by tools other than patents?

-What about regulatory data protection, trade secret, blockchain &

smart contracts?Matisse 1&2 room

Licensing Opportunities and

TechnoMarket

Van Gogh 3 room

IDEASummit

Matisse 3 room5.15 pm6.15 pm

6.30 pm

How can experienced entrepreneurs become involved and support today’s life sciences

start-ups?Van Gogh 1&2 room

7.00 pm BIOPARTY BIOPARTY

11

12

DAY TWO Thursday 1st December

12




and tech transfer


stage innovation


by Réseau SATT Partnering Hosted event8.00 am9.30 am REGISTRATION AND WELCOME WELCOME

One- to-one


WELCOME

9.30 am11.00 am How can industry and

investor incubator models accelerate

research translation?Van Gogh 1&2 room

9.45 am – 11.00 am Licensing Opportunities

and TechnoMarket INFECTIOLOGY

& VACCINES Van Gogh 3 room

SIRIC ONCOLille Days

Eurotop room

11.00 am11.30 am COFFEE BREAK COFFEE BREAK COFFEE BREAK11.30 am1.00 pm Universities - a short

or long-term partner for spin-offs?

Matisse 1&2 room

Sponsored by

How to spark the interest of VCs for Series

A financing?Van Gogh 1&2 room

Start-up slams Van Gogh 3 room


Eurotop room

1.00 pm 2.30 pm LUNCH Lille Metropole LUNCH LUNCH2.30 pm4.00 pm

To spin or not to spin?

Van Gogh 1&2 room

Licensing Opportunities and TechnoMarket

RESEARCH TOOLS Van Gogh 3 room


Eurotop room4.00 pm5.00 pm How can the deal-making

process be accelerated by standardisation and framework agreements?

Van Gogh 1&2 room

5.00 pm6.00 pm END OF BIOFIT 2016 END OF BIOFIT 2016

CONFERENCES

1313




and tech transfer


stage innovation


by Réseau SATT Partnering Hosted event8.00 am9.30 am REGISTRATION AND WELCOME WELCOME

One- to-one


WELCOME

9.30 am11.00 am How can industry and

investor incubator models accelerate

research translation?Van Gogh 1&2 room

9.45 am – 11.00 am Licensing Opportunities

and TechnoMarket INFECTIOLOGY

& VACCINES Van Gogh 3 room


Eurotop room

11.00 am11.30 am COFFEE BREAK COFFEE BREAK COFFEE BREAK11.30 am1.00 pm Universities - a short

or long-term partner for spin-offs?

Matisse 1&2 room

Sponsored by

How to spark the interest of VCs for Series

A financing?Van Gogh 1&2 room

Start-up slams Van Gogh 3 room


Eurotop room

1.00 pm 2.30 pm LUNCH Lille Metropole LUNCH LUNCH2.30 pm4.00 pm


Van Gogh 1&2 room

Licensing Opportunities and TechnoMarket

RESEARCH TOOLS Van Gogh 3 room


Eurotop room4.00 pm5.00 pm How can the deal-making

process be accelerated by standardisation and framework agreements?

Van Gogh 1&2 room

5.00 pm6.00 pm END OF BIOFIT 2016 END OF BIOFIT 2016

14

CONTACT DETAILSSano Pasteur welcomes information about new partnership opportunities. Each opportunity is carefully evaluated and reviewed by our dedicated team.

Please contact:

Jean-Marc Renard, MS, MBAVice President, Corporate DevelopmentTel: +33 4 3737 3480Email: jean-marc.renard@sano pasteur.com

Sano� Pasteurwww.sano�pasteu r . com

Partnership opportunities with Sano PasteurSano Pasteur, the vaccines division of Sano , is seeking partners who will share the company’s pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world.

W

Sano Pasteur is interested in partners who will share in the pursuit of innovation and our drive for excellence, while becoming a part of our market success story. “We welcome the opportunity to evaluate technologies related

to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases,” said Roman Chicz, PhD.

Sano Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, govern-ment bodies, biotechnology companies and con-tract research organizations. The company's col-laborations cover virtually all aspects of vaccine development, including early-stage research.

Examples of current partnerships and technol-ogy investments include: vaccines for dengue fever, Japanese encephalitis, S. pneumoniae,

A company partnering with Sano Pasteur interacts with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed succesfully and nur-tured for the mutual bene t of all parties.

This approach utilizes the value-added Sano

Pasteur alliance management capability, which focuses on the relationship by facilitating open communication, trust, understanding and clear expectations across the project lifespan. Combined with the technical competency of the alliance, this balance provides a well rounded environment for your technology to ourish.

Sano Pasteur is interested in potential partnering opportunities in the eld of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:

Characterization and assay of immune responses and disease markersAnimal models of human diseases

Biological markers for evaluating the

interventions

In vitro models of human tissues, including the immune system

Epidemiological studies relevant to the use of vaccines and immunotherapeutics

Tools for improving vaccine and monoclonal antibody research, development and production Development and application of new technologies in the areas of genomics and proteomics

Prokaryotic or eukaryotic cell lines for antigen production

Fermentor and bioreactor technology

Disposable systems

Online testing

Process automation

Preservatives and stabilizers

Bioinformatics techniques for modeling, data handling and analysis

Anti-counterfeiting technology

Vaccines, monoclonal antibodies and supporting technologies for prevention and treatmentof infectious diseases

Novel antigens and methods for antigen discovery and characterization Carrier proteins and protein-

polysaccharide conjugation methods or alternative technologies

Vaccine vectors suitable for nasal or oral use

New ways to administer vaccines

Agents to enhance vaccine immune responsesAdjuvants and immunomodulators

Vaccine vectors and delivery systems intended to enhance or modify immune responses

Biological and immunological studies to further characterize adjuvants and immunomodulators

e are not only at the forefront of conquering newly targeted infectious diseases, but also leading the way in

expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

and M. tuberculosis; pediatric combination vaccines; rabies monoclonal antibodies; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.

Roman Chicz, PhDHead, External Research and DevelopmentTel: +1 617 866 4562Email: roman.chicz@sano�pasteur.comSano� Pasteur recently signed an agreement

with SK Chemical Co. of South Korea to co-develop an innovative pneumococcal conjugate vaccine

15

New models required for academic, biotech and pharma collaborations

30th Nov 11.30 am – 12.00 pm

KEYNOTE

PETER GRUSS former president, the max planck society, chair of the siemens technology and innovation council

PLENARY SESSION

Is Europe competitive enough in Life Sciences innovation?

Discussion continues around Europe’s position on the global stage of life sciences innovation. There are significant differences in financing, risk assessment and marketing models which could lead to underestimating Europe’s potential. Do the key actors have all the elements in order to evaluate the state of Europe’s life sciences market correctly?

Come to this exciting session and find out from leading global experts.

Ron Newbold vp external r&d innovation, pfizer worldwide research & development

Piyush Unalkat head of technology transfer investments, iti, european investment fund

Laurent Lévy ceo, nanobiotix

Franck Lescure partner, auriga partners

Johan Cardoen managing director, vib

30th Nov, 12.00 pm – 1.00 pm

moderator. John Carroll editor, endpoints

amphitheatre pasteur


16

How can industry and investor incubator models accelerate research translation?

Various forms of incubator models programmes have appeared over recent years. What are the complementarities with traditional academic incubators and how can industry and incubator models help start-ups to grow. What are the limits and real advantages of these new models? Hear the success stories of incubated companies and incubator models and retain best practices.

How can the deal-making process be accelerated by standardisation and framework agreements?

The sector is looking for the best way to accelerate the deal-making process and push innovation forward. Does the answer reside in standardised contracts and what is their real value? With all the associated constraints, how can the deal-making process be positively influenced: Is standardisation a challenge or an opportunity?

moderator Sabine Louet ceo, sciencepod

Magnus Björsne ceo, astrazeneca bioventurehub

Einat Zisman ceo, futurx

Christophe Guichard director, eclosion

moderator Nicolas Carboni president, satt conectus alsace

Kees de Ruig business development manager, eatris

Lorraine Sautter director legal affairs, inserm transfert

Paul Hermant partner, bird & bird

TRACK 11st Dec, 9.30 am - 11.00 am | van gogh 1&2 room

1st Dec, 4.00 pm - 5.00 pm | van gogh 1&2 room

BEST PRACTICES IN COLLABORATIVE RESEARCH

17

Content, finances and governance of public-private collaborations around the world

Do public-private collaborations work the same way around the globe? What best practices can one collaboration learn from the other? Should that be regarding content, financing and governance of these partnerships, what are the Do’s and Don’ts when shaping and managing public-private collaborations? Find out with 15 world renowned seasoned experts from USA, Europe, Israel and Asia, ready to answer your questions and share their experience.

30th Nov 2.30 pm – 5.15 pm |Artois 1 room

Michael Rossbach vp pharma partnering, vela diagnostics

Johan Cardoen managing director, vib

Catherine Rochat director, r&d alliance management, institut de recherches internationales servier (iris)

Vered Caplan ceo, orgenesis

Corinne Szilagyi senior partner, biotech développement conseils

Einat Zisman ceo, futurx

Franck Lescure partner, auriga partners

Christian Policard chairman of the business development sub-committee, france biotech

Erik Tambuyzer co-founder & chair of the board, biopontis alliance

Armelle Gaussin head of neW opportunities business development & licensing, debiopharm international

Luc Mathis vice president of neW ventures, cellectis

François Garnier executive vice president general, counsel, ipsen

Stéphane Boissel chief executive officer, txcell

Brion Berman senior licensing associate, office of research and commercialization, ucf

30th Nov 2.00 pm – 2.30 pm |Artois 1 room

WORKSHOP

moderator. Christian Policard member of the board chairman of the business development sub-committee, france biotech

Panorama de l’industrie des sciences de la vie®

en France par France Biotech

18

What is the best background for the CEO of an academic spin-off?

Certain researchers have become successful entrepreneurs; however, an external CEO is often brought into a spin-off company. What is the optimal profile? How can the new CEO create a winning scientific team? What is the importance of the role of the CEO to lead the company and face market and business challenges? Is a good CEO born or made?

moderator Stefan Lensky epimab therapeutics

Kai Simons ceo, lipotype & director emeritus, max planck institute cbg

Frank Hensel investment manager, high-tech gründerfonds

Daisuke Sugiyama adviser, kansai technology licensing adviser

30th Nov, 2.30 pm – 4.00 pm | matisse 1&2 room

TRACK 2 KEY ISSUES IN LICENSING AND TECH TRANSFER

Universities - a short or long-term partner for spin-offs?

Come and listen to our international panelists discuss this inspiring question. How does a university decide on its involvement with a spin-off? How do universities handle IP transfer and POC funding? Our panelists will share best practices from their experience of previous and current collaborations.

session sponsored by

moderator Alexandra Carrel certified licensing professional, cabinet carrel

Paul Ashley deputy head of tech transfer, isis innovation

Stefan K. Nilsson ceo, lipigon Adi Elkeles vp business development life sciences, ramot

1st Dec, 11.30 am – 1.00 pm | matisse 1&2 room

19

Could your innovations be protected efficiently by tools other than patents? What about data protection, trade secrets, blockchain and smart contracts?Are you making the most of your possibilities for IP rights protection? This roundtable discussion with legal, scientific and entrepreneurial experts from the life sciences sector aims at broadening the vision of biotech actors for a successful IP strategy. In particular, the session will focus on the various tools and solutions available in addition to patent protection : (1) What can we learn from the new European commission directive on trade secrets? (2) How can you implement a synergistic protection including both patents and Regulatory Data Protection? (3) How may blockchain and smart contracts be implemented in IP protection or as an alternative to the common tools?

WORKSHOP 30th Nov, 4.30 pm – 6.00 pm | matisse 1&2 room

moderator Rafaela Kunz consultant, insea consulting

Cécile Théard-Jallu attorney, de gaulle fleurance & associés

Nicolas Marro patent attorney, cabinet beau de loménie

Thomas N’Dem ceo, beleev


A spin-off is one of the most important decisions in the development life cycle. How should TTOs choose between licensing out IP, creating a spin-off or a contract-based R&D collaboration? What translation efforts don’t match these classic TTO models? Find out at this truly global discussion between experts from three continents.

moderator Ivan Baines coo, max planck institute cbg

Katja Rosenkranz principal, v-bio ventures

Andrew Tingey director of healthcare licensing, imperial innovation

Doo Young Jung head of tech transfer office, korean institute of chemical technology

Vivian Berlin director business development harvard university | office of technology development

1st Dec, 2.30 pm – 4.00 pm | van gogh 1&2 room

20

Committed to the VC business: why and how universities take part in new venture funds?

There is a new trend of European academic investing to support early stage projects. Starting with a presentation of the recently launched Apollo Therapeutic Funds, our panel will discuss the impact of this new pioneering joint venture and how it will support the translation of ground-breaking academic science.

30th Nov, 9.30 am – 11.00 am | van gogh 1&2 room

TRACK 3 FUNDING EARLY STAGE INNOVATION

moderator Lisa Urquhart editor, ep vantage

Iain Thomas head of life sciences, cambridge enterprise

Jasper Bos head of life sciences, merck ventures

Thomas Hanke evp, head of immunology and inflammation, evotec

Jakob Busch-Petersen, senior director, external innovation group, roche innovation center

How to create a European seed capital market?

Many initiatives exist at national levels to improve access to capital. How can we support this at a European level and what’s at stake? How to support the creation of a European seed capital market in order to finance research translation from academia? Investments are going into well-established companies, how can we make sure that smaller companies are benefiting from the same funding opportunities as more well-established structures? How can we increase European seed capital, so crucial for innovation to continue?

30th Nov, 2.30 pm – 4.00 pm | van gogh 1&2 room

moderator

Cormac Sheridan journalist, bioworld today

Michèle Ollier partner and cofounder, medicxi

Sam Fazeli head of bloomberg intelligence, emea; senior pharmaceutical analyst, bloomberg intelligence

Soren Moller managing partner, novo seeds

Axel Kalinowski manager - continental europe, london stock exchange

21

How can experienced and successful entrepreneurs become involved and support today’s life sciences start-ups?

The most valuable assistance for start-ups is advice about the environment and mistakes to avoid. The best way to promote innovation is mentoring and accelerating promising projects and encourage them to develop in the right direction. Experienced entrepreneurs will talk about how they have contributed to the growth of young companies and share how they have advised and financed young entrepreneurs.

moderator

Garold Breit director business development initiative, city of charleston

Daniel Green ceo, yaqrit

Speaker to be confirmed

30th Nov, 5.15 pm – 6.15 pm | van gogh 1&2 room

How to spark the interest of VCs for Series A financing?

Some entrepreneurs often have difficulty attracting Series A financing although this may be the most important step in funding life sciences projects. Hear from biotechs that have succeeded in attracting Series A financing and from venture capitalists experts that will share tips for success.

1st Dec, 11.30 am– 1.00 pm | van gogh 1&2 room

moderator.

Gerald Law chief executive, innovation forum

Philippe Monteyne vc partner, fund +

Thierry Laugel managing partner, kurma partners

Roberto Gradnik ceo, ixaltis

Bart Wuurman ceo, ddf ventures

22

van gogh 1&2 room

Organised by AFSSI, the French Association of Outsourcing and Innovative Companies, the AFSSI conference gathers over 100 French entrepreneurs from R&D, life sciences, big company decision makers, academic research leaders, governmental regulators and investors to discuss the best relationships within the new landscape of industry R&D cooperation.

The conference will focus on the growing number of small and medium technology companies driven by the needs of biopharma companies to optimise research costs and of academia to advance research programmes to maturity.

www.afssi.fr/conference


Organised by EGID, the European Genomic Institute for Diabetes, the 4th edition of the EGID Symposium is hosted by BioFIT and organised in collaboration with IDEA Summit.

The Steering Committee and speakers – world leaders in their fields – will present the latest scientific advances in diabetes and related disorders. This year, EGID Symposium is about “Liver, Diabetes and Cardiovascular Risks”.

This symposium provides an opportunity for young researchers to present their work during poster presentations and to win the «Best Poster Award» (€1,000).

www.egid.fr

European Genomic Institute for Diabetes

29th Nov

29th Nov 30th Nov

HOSTED EVENTS BY

van gogh 3 room

TechnoMarket is an event created by Réseau SATT to discover innovative technologies from public research. It is a real market place for companies ready to innovate. The technologies presented will be selected by an expert committee with a call for applications stemming from French and European transfer structures. *Activity organised in partnership with BioFIT Licensing Opportunity Presentations

30th Nov1st Dec

organised by

INNOVATION IN CARDIOMETABOLIC DISEASES

Discover innovative technologies during 2 days of pitch presentations and poster exhibition dealing with research tools, oncology, infectiology and vaccines, cardiology, neurology and schedule B-to-B appointments to meet, exchange and deepen the addressed issues.

www.technomarket.fr

23

eurotop room

Organised by ONCOLille, an integrated cancer research consortium of clinicians and researchers in Lille, the ONCOLille Days feature a programme of conferences and poster presentations on oncology. ONCOLille is promoting a swift transfer between basic, translational and clinical researches in the Lille area on two major issues of modern oncology: the tumor resistance to loco-regional treatments and the tumor dormancy (or persistence) after remission.

During the ONCOLille Days scientific symposium, researchers and clinicians will present their latest discoveries on the molecular mechanisms explaining the tumor cell resistance to treatment (MET receptors, MUC4-ErbB2 complexes, calcium canals involvement, immunosuppressive role of regulatory T cells, etc.) or explaining cancer cell persistence after treatment (immune evasion due to PD1-PDL1 interactions, tumor cell clonality, etc.). Drug design strategies, new imaging technologies, innovative pre-clinical models and nanotechnologies developed to support those researches, will also been presented and discussed.

www.oncolille.fr

30th Nov 1st Dec

matisse 3 room

This 4th edition of the IDEA Summit is organised by Lund University Diabetes Centre, Eurasanté and the Nutrition Health Longevity cluster, and supported by Ascenion, AstraZeneca, Novo Nordisk and Sanofi, in collaboration with BioFIT Event and EGID Symposium.

The IDEA Summit is a unique European event dedicated to collaborative research and to technology transfer in the field of diabetes.The summit aims to be a platform for dialogue and to strengthen the links between academia and industry.At previous editions of the IDEA Summit, academia and industry enhanced their understanding of each other’s strengths and driving forces. However, there is still a significant need to develop new ways of stimulating interaction and sharing knowledge and resources more effectively. The organisers want to go even further by involving patients and creating long-term links between academia and industry.

www.idea-summit-diabetes.com

30th Nov 1st Dec

organised by

sponsored by

INNOVATION IN DIABETES INNOVATION IN ONCOLOGY

Invest for Success organised by

24

HOSTED EVENTS PROGRAMME

8.30 am

29th Nov Van Gogh 1&2 room

29th Nov Amphitheatre Pasteur

30th Nov 1st DecVan Gogh 3 room

9.30 am

Registration & welcomeRegistration & welcome

10.00 am

Unfair Competition: Seisine focus and AFSSI Mobilization

Building sustainable relationships between industrial life sciences R&D

stakeholder

Pitches and posters

(Oncology)

Pitches and posters

(Infectiology & vaccines)

10.20 am

10.30 am

10.40 am

11.00 am

11.30 am

Break Break Poster exhibition & networking break

12.00 pmAFSSI Summer school: 2016 edition review;

Launch of the 2017 edition: format, themes, synergies,

recruitment of contracto

BioFIT Plenary Session

BioFIT Start-up

slams12.30 pm

1.00 pm

2.00 pm Lunch Lunch

2.30 pm

3.00 pmInternational actions: Objectives and ways for AFSSI’s members

BioFIT Start-up

slams

Pitches and posters

(Research tools)

3.30 pm

4.00 pm

4.30 pm

Break Poster exhibition & networking break

5.00 pm

Animation facilities: Web services, webinars, regional

workshops, pavilions, etc.Q/A

Pitches and posters

(Neurology &

Cardiology)

5.30 pm

6.00 pm

European Genomic Institute for Diabetes

24

9.00 am Registration

9.30 am Intruduction and welcome

9.45 am Post translational modifications

in liver fibrosis

10.25 am Fatty liver, lipoprotein metabolism

and cardiovascular risk

11.00 – 11.30 am Coffee Break

11.05 am Hepatic Steatosis

11.45 am Poster Session and Lunch

1.00 – 2.30 pm Lunch

2.30 pm Alterations in DNA methylation

and type 2 diabetes

3.10 pm Histological classification

of NAFLD: limits and perspectives

3.50 pm Coffee break

4.15 pm Immunoregulation of liver fibrosis:

novel targets

4.55 pm Best Paper Award

5.15 pm Conclusions and EGID’s surprise

25

8.30 am

30th Nov 1st Dec 30th NovMatisse 3 room

9.30 am

Registration & welcome Registration & welcome

10.00 am

Are the metabolic syndrome and insulin resistance a breaking

ground for innovation?

8.00 am

Partnering during BioFIT

10.20 am

10.30 am

10.40 am

11.00 am

11.30 am

Break

12.00 pm

BioFIT Plenary Session BioFIT Plenary Session12.30 pm

1.00 pm

2.00 pm Lunch


2.30 pm

2.50 pmWhat are pharma’s

needs in terms of licensing and

collaborative research in diabetes? Partnering

during BioFIT

3.30 pm

4.00 pm

4.30 pm

Break

5.00 pm5 minutes to persuade

(research projects & start-up pitches)

5.30 pm

6.00 pm

Most successful & innovative start-ups in

diabetes in 2015/20166.30 pm

1st Dec

Innovative tools and pre-clinical models x 1

Break

Innovative tools and pre-clinical models

x 4

Lunch

Innovative tools and pre-clinical models x1

Human and social sciences x 2

Clinical investigations x1

ONCOLILLE 2 Strategic Workshop

25

Innovative therapies against tumor resistance

and dormancy x 5 10.20


Eurotop room

26

Value through Innovation

At Boehringer Ingelheim we believe in forming durable partnerships to develop innovative new medicines in areas of high unmet need. Our relationships range from discovery research, development and technology collaborations to clinical and commercial partnerships and full-scale, long-term strategic alliances.

Boehringer Ingelheim is researching, developing, manufacturing and marketing new medications of high therapeutic value for patients. It is one of the world’s 20 leading pharmaceutical companies and operates globally with a total of more than 47,700 employees.

In 2014 Boehringer Ingelheim achieved net sales of about 13.3 billion euros and spent 2.7 billion euros on R & D corresponding to 19.9 per cent of its net sales.

We invite you to find out more about partnering with us by visiting http://partnering.boehringer-ingelheim.com

Working together for better health

www.boehringer-ingelheim.com

anz_bi_F&E_A6quer_101116.indd 1 10.11.16 08:39

o^mmloq=^

OMN= 9, rue Boissy d’Anglas

75008 Paris - FranceTel.: + 33 (0)1 56 64 00 00

222, avenue Louise 1050 Brussels - BelgiumTel.: + 32 (0)2 644 01 64

www.degaullefl eurance.com

110+ LAWYERS AND PARALEGALS AN INTEGRATED FULL SERVICE APPROACHCONNECTED TO LIFE SCIENCES

Manuel Ortiz, Development Director

+33 (0) 6 30 73 86 62mortiz@dgfl a.com

Cécile Théard-Jallu,Partner

+ 33 (0) 6 61 92 05 29ctheardjallu@dgfl a.com

Your contacts at the Biofi t 2016 conference:

We cover all legal needs of Healthcare & Life Sciences actors on transactional & litigation matters

throughout the life cycle of products & services

A5_BioFit_DGFLA 2016.indd 1 09/11/2016 15:10:36

27

Coaching INPI, a range of services to support business growth

Secure your developmentby improving your IP practices

Get financial supportto implement your IP policy

Design and optimise your IP strategy to increase

your competitiveness

[email protected]

Meet your INPI expert for further information

www.inpi.fr

COMMITTED TO THE LIFEA BIOPHARMACEUTICAL GROUP

OF HUNDREDS OF THOUSANDS OF PATIENTS SUFFERING FROM SERIOUS AND OFTEN RARE DISEASES WHO ARE TREATED EACH YEAR WITH OUR BIOPHARMACEUTICALS.

The LFB Group specializes in biopharmaceuticals: plasma-derived medicinal products, recombinant proteins, monoclonal antibodies and advanced therapies.

The LFB Group manufactures its biological medicines in 5 bioproduction plants – 4 of which are in France – and markets its products in more than 40 countries.

Follow us on social networkswww.groupe-lfb.com

28

TECHNOMARKET AND PRESENTING TECHNOLOGIES

Discover Life Sciences latest innovationsDiscover the projects at the Poster Area and join the Presenting technologies sessions to listen the 30 most innovative projects, selected by our jury of experts, pitch in the following categories:

Neurology & Cardiology

Oncology

Research tools

Infectiology & Vaccines

Discover the most innovative start-upsless than 5 years old or about to be created

•During the Start-up pitches•At their dedicated meeting spaces in the innovation area.If you wish to learn more about the selected projects, please get the “Presentation Sessions” book or visit our website: www.biofit-event.com

START-UP SLAMSBY

START-UP SLAMS PROGRAMME

DAY 1 2.30 -4.00 pm | Van Gogh 3 room

APTEEUS*VITAMFERO S.A.VIROVETSENCET*KANGSTEM BIOTECH CO., LTD.NOVAPTECH

DAY 2 11.30 -1.00 pm| Van Gogh 3 room

E-ZYVEC*SPECTRALYS BIOTECHCEFO CO., LTDIMMUNE INSIGHT*1CRYOBIO AG

*Visible on the Lille Northern France Biocluster pavilion (B8)

29

DAY 1 | Van Gogh 3 room 30th Nov DAY 2 | Van Gogh 3 room 1st Dec

ONCOLOGY ............................9.45 -11.00 am

SATT Grand Centre Diagnostic and stratification of colorectal cancer for a better management of patient care protocol.

SATT Nord New peptide-based drug with anti-angiogenic properties.

Ghent University Poly(2-oxazoline)s for a new generation of Cancer Drug Delivery.

IDF Innov Potent blocker of HER2 receptor for treatment of metastatic breast cancer.

SATT Sud-Est Kinase Inhibitors & Cancer

KRICT Small molecule lead compounds for colorectal cancer treatment through TNIK modulation.

SATT Nord ProNGF: New target to counter resistance mechanisms in breast cancer.

SATT Grand Centre Dual PI3K and mTOR inhibitors as promising drugs to treat cancer.

NEUROLOGY ............................4.30 -6.00 pm

SATT Grand Centre Preventing neuropathic pain induced by mastectomy

SATT Sud-Est Neuropain and chronic pain prevention

SATT Nord DIVE: Dopaminergic stimulation by continuous intracerebro ventricular delivery of anaerobic dopamine in Parkinson’s disease.

IGTP Biomarkers for the diagnosis of dementia with Lewy bodies

Ouest Valorisation New generation of neuroprotectants: an original way to treat and prevent acute and chronic neurological diseases

SATT Grand Centre Preventing neuropathic pain induced by chemotherapy.

CARDIOLOGY Aquitaine Science Transfert CARMIDO

SATT NORD Therapeutic potential of a molecule that modulate platelet function and thrombosis.

INFECTIOLOGY & VACCINES ...........................9.45 -11.00 am

Aquitaine Science Transfert Bioactive Prosthesis.

IDF Innov First effective vaccine against chlamydia infection.

SATT Sud-Est Influenza antivirals

FIST SA Adenoviral coat protein delivery vehicles for use as a vaccine platform.

Aquitaine Science Transfert FibroCOPD

SATT Grand Centre New antibody fragments to treat ocular toxoplasmosis.

IDF Innov New small molecules to purge HIV reservoirs.

RESEARCH TOOLS ............ 2.30 -3.15 pm

IOCB-TTO A rapid NTP-transporter as a tool for staining DNA in living cells.

Linksium MAGIA

PEACCEL Disruptive mixed in vitro-in-silico approach for protein engineering and screening.

IOCB-TTO iBodies: Modular Polymer-Based Synthetic Antibodies

TECHNOMARKET AND PRESENTING TECHNOLOGIES PROGRAMME

30

EXHIBITORS’ LIST4P-PHARMA ........................................I11

ABLIANCE ...........................................D8

ADMESCOPE ......................................D4

AFSSI SCIENCES DE LA VIE .......... J9

BIOSIMS TECHNOLOGIES.... J9

DRUGABILIS .............................. J9

HISTALIM .................................... J9

ITEC SERVICES .......................... J9

OROXCELL ................................. J9

PORSOLT .................................... J9

RD-BIOTECH .............................. J9

SMALTIS ..................................... J9

ALCAMI CORPORATION ............... H10

AQUILAB .............................................G6

ASTP-PROTON ...................................G4

ATLANPOLE BIOTHERAPIES .....D7

POLEPHARMA ..........................D7

BIOGENOUEST .......................D7

ID2SANTE .................................D7

BACCINEX SA .....................................C4

BACHEM AG ....................................G10

BIOBANQUES - INSERM US13 .......B6

BOOST4HEALTH ................................ E2

CELLVAX, SAS ......................................B7

CITOXLAB AND ATLANBIO ............... J5

CZECHINVEST ....................................D6

DELPHARM BIOTECH ....................... H6

EGID .................................................... H9

ERDYN .................................................G9

EU-JAPAN ............................................ F8

EUROFINS BIOPHARMA PRODUCT TESTING.............................................. H4

EUROFINS PHARMA DISCOVERY SERVICES ...........................................H12

EUROSCREEN FAST .......................... H3

GENECODE ........................................D1

IDBS ......................................................C5

IMODE ................................................. E2

INPI ......................................................G3

INNOVATION AREA

1CRYOBIO

CEFO

KANGSTEM BIOTECH

NOVAPTECH

SPECTRALYS BIOTECH

VIROVET

VITAMFERO

KIC-EUROPE.........................................F7 LIFE & SOFT .......................................... I6

LILLE NORTHERN FRANCE BIOCLUSTER .................................... B8

EURASANTE .............................B8

NUTRITION HEALTH LONGEVITY CLUSTER .............B8

ALSACE BIOVALLEY .................B8

AMYLGEN.................................B8

ERAS INGENIERIE ...................B8

GENOSCREEN ........................B8

ORIGINAL PROCESS ..............B8

TECHNOLOGY PLATFORMS IN HAUTS-DE-FRANCE ................B8

VALBIOTIS .................................B8

LILLE NORTHERN FRANCE BIOINCUBATOR .................. B8

APTEEUS ....................................B8

E-ZYVEC ....................................B8

IMMUNE INSIGHT .................B8

PRECIGENICS ..........................B8

SENCET .....................................B8

VAXINANO ..............................B8

X’PROCHEM .............................B8

MEDICEN PARIS REGION ................C2

MINNETRONIX ................................. H5

MYCARTIS .........................................G11

OCR ......................................................D5

ONCOLILLE ........................................G8

PHARMA LOGISTICS CLUB .............. F6

RÉSEAU SATT ..................................I12

SATT CONECTUS ALSACE .... I12

SATT TOULOUSE TECH TRANSFER ..................... I12

AQUITAINE SCIENCE TRANSFERT ............ I12

SATT AXLR ................................ I12

SATT GRAND CENTRE ........... I12

SATT GRAND EST .....................12

SATT ILE-DE-FRANCE INNOV ..................................... I12

LINKSIUM ................................ I12

SATT LUTECH ........................... I12

SATT NORD ............................. I12

SATT OUEST VALORISATION ....................... I12

SATT PARIS-SACLAY ............... I12

SATT SUD-EST ......................... I12

PULSALYS SATT LYON ST-ETIENNE ................. I12

SIMV .....................................................D3

SOFISE .............................................. G12

SOLADIS ..............................................D2

VIALTO ................................................. F5

31

EXHIBITION PLAN

@

Press areaPartnering

Desk

i

Innovation area

Lunch area

Lounge area

Inte

rnet

Term

inal

s

Access to the conferences ENTRANCE

B6

C2B7 D2C5

D1C4

E2D4

D5

D6

D7

D8

B8

I12

J9

D3

F5 G3 G8

G9 H3

G10

G11

G12 H12

H10

H9

I11 J5

I6

H5

H4

H6

F6

F7

F8 G6

G4

15-24

1-14

25-4057-70

71-83

41-56

COFFEE BREAK AREA

PARTNERINGBOOTHS

32

4P-PHARMA ............................................................ I11 Campus de l’Institut Pasteur de Lille 1, rue du professeur Calmette - 59000 Lille -France

Website www.4p-pharma.com

Phone+33 (0)9 72 84 72 64

Contact Revital Rattenbach

Email [email protected]

4P-Pharma is a company focusing on preclinical research and specializing in the development of new, innovative and first-in-class medical drugs and therapeutic agents, in the fields of oncology and inflammatory diseases. Our model is based on a co-development, co-share, and co-risk basis. We partner with universities, TTOs, VCs, investors, biotech and pharma companies to translate early stage projects into products.

ABLIANCE ...........................................................D8 21 Quai Clos des roses 60200, COMPIEGNE - France

Website www.abliance.com

Phone +33(0)3 44 20 61 30

Contact Mylène Wasielewski


ABLIANCE is an antibody manufacturer well established in Europe as a supplier of antibodies for research and diagnostics.

ANTIBODY SERVICES:

-mAb development

-mAb production

-pAb production

-Purification, Conjugation, Fragmentation

-Cell banking

SECONDARY ANTIBODIES: an extensive range of species, specificities and labels, enabling sensitive and reliable detection in ELISA, WB, IHC, immunocytology, flow cytometry…

IVD REAGENTS: exclusive distributor of BIOLABO reagents in FRANCE

ADMESCOPE ........................................................... D4 Typpitie 1 90620 Oulu - Finland

Website www.admescope.com

Phone +358 45 87 99 032

Contact Minna Komu


Admescope is a CRO providing the pharmaceutical industry with tailor-made services to drug discovery in the area of ADME-Tox. The service offering is widely spread from highly tailored studies to High Throughput Screening (HTS). Our unique top-notch expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right study assay can always be found whether in the discovery or lead optimisation phase.

AFSSI SCIENCES DE LA VIE ................................J9 Biocitech, 102 Avenue Gaston Roussel 93230 Romainville - France

Website www.afssi.fr

Phone +33 (0)6 86 16 99 89

Contact Claude-Alain Cudennec


The Association Française des Sociétés de Services et d’Innovation (AFSSI), French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners. AFSSI represents over 120 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs.

33

ALCAMI CORPORATION ...........................H10 Vliesvenweg 1 6002 NM Weert - Netherlands

Website www.alcaminow.com

Phone 3 36 46 07 69 65

Contact Philippe Martel


AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form Alcami, a world class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stab

AMYLGEN ...................................................................B8 2196 Boulevard de la Lironde 34980 Montferrier sur Lez - France

Website www.amylgen.com

Phone +32 (0)6 18 46 53 66

Contact Vanessa Villard


Amylgen is a preclinical CRO offering in vivo models of psyhiatric and neurodegenerative diseases. By combining a strong experience in behavior with expertise in biochemistry, neurochemistry and histology, Amylgen offers an integrated service. Your product can be evaluated on multiple aspects of brain function including memory, depression, anxiety. All behavior efficacy may be supported by relevant analysis helping the understanding of the mechanism of action of your product on brain health.

APTEEUS ............................................................. B8 3, rue du Professeur Laguesse 59000, Lille - France

Website www.apteeus.fr

Phone +336 37 27 79 70

Contact Terence Beghyn


APTEEUS is innovating in the field of individualized medicine by developing treatments for patients with rare and orphan diseases. Our innovative process engages patients in the development of the drug on the basis of the response of their cells to treatment. The repositioning of the drug resulting is less risky, less expensive and faster than the development of new molecules. We best respond to medical need in the field of rare and orphan diseases, taking into account the individuality of each.

AQUILAB ...........................................................G6 250 Rue Salvador Allende 59120, Loos - France

Website www.aquilab.com

Phone +33 (0)3 69 61 51 51

Contact David Gibon


AQUILAB develops advanced software solutions to improve treatment consistency and data quality in Clinical Trials. Share Place is a cloud-based collaborative platform, dedicated to streamline your workflow, fully connected with advanced expert tools allowing image analysis and review. The platform can meet the requirements of any clinical study, as it offers personalized tools such as workflow management, eCRF, medical imaging or radiotherapy plans review and online patient reported outcomes.

34

AQUITAINE SCIENCE TRANSFERT .............I12 bâtiment A31, 351 cours de la libération 33405, Talence - France

Website www.innovations-aquitaine.com

Phone +33 (0)6 26 53 43 97

Contact Jean-Luc Chagnaud


Aquitaine Science Transfert is the TTO for the south west of France, covering 6000 researchers and 135 laboratories. We represent the regional academic research : Bordeaux University, INSERM, CNRS, Pau University, Bordeaux Polytechnic Institute, ... Since opur inception in july 2012, we have signed 21 licence agreements, patented 143 technologies and created 7 startups. Representing 65% of our projects, health and biomedical are strategic to our business development.

ASTP-PROTON .......................................................G4 Stationsweg 28a 2312AV Leiden - The Netherlands

Website www.astp-proton.eu

Phone +31 (0)7 17 11 35 11

Contact Anne Disseldorp


ASTP-Proton is the premier and leading Europe-wide association for professionals involved in the transfer of knowledge, science and technology between universities and industry with more than 800 members from more than 40 countries. In order to facilitate the exchange of best practices among K/TT professionals and strengthen the network of our members, ASTP-Proton organises several networking events as well as professional development trainings throughout the year in various European cities.

ATLANPOLE BIOTHERAPIES ........................... D7 Château de la Chantrerie - 95 route de Gachet 44307 NANTES - France

Website www.atlanpolebiotherapies.com

Phone +33 (0)2 40 25 27 20

Contact Lynda Guerineau


Atlanpole Biotherapies is a French clusters dedicated to health. It gathers 104 companies, 56 research units, 2 Hospital Universities and 1 veterinary school, Our main areas of excellence are Immunobiotherapy, Radiopharmaceuticals, Regenerative Medicine and Innovative technologies for biotherapies. Atlanpole Biotherapies mission is to boost innovation mainly through public/private partnerships and international networking (through 30 partnerships with clusters).

BACCINEX SA ...........................................................C4 Rue de la Source 3 2822 Courroux - Switzerland

Website www.baccinex.com

Phone +41 324 207 640

Contact Bénédicte Broggi


Baccinex is the preferential and highly recognized one-stop Swiss partner (CMO) for contract manufacturing of sterile lyophilized and liquid dosage forms. We routinely supply clinical medication for phase I, II and III trials to our (bio)pharmaceutical clients.

We offer a complete service including:

• Liquid or lyophilized drug product manufacturing (under aseptic conditions, in vials or ampoules)

• Secondary packaging (randomized labeling included)

• QC analytics (physicochemical and microb

35

BACHEM AG .......................................................... G10 Hauptstrasse 144 4416 Bubendorf - Switzerland

Website www.bachem.com

Phone +41 585 952 021

Contact Gilles Parmentier


Bachem is specialized in the process development and manufacturing of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach and towards its customers, Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides

BIOBANQUES - INSERM US13 ......................B6 Hôpital de la Pitié Salpêtrière 47, bd de l’Hôpital 75651Paris Cedex 13 - France

website www.biobanques.eu

Phone +33 (1) 42 16 25 45

Contact Hamid ECHCHAKIR


The national infrastructure BIOBANQUES - Inserm US13 is dedicated to biomedical research using human samples and associated data. It aims to accelerate biomarker development and translational research. BIOBANQUES provides services to researchers: one stop-access to biological samples from 91 french biobanks covering the whole spectrum of diseases from rare to common complex diseases, and offers related expertise in ethics, methodology, stats, bioinformatics, biosafety, biosecurity and quality.

BIOGENOUEST ....................................................... D7 Biogenouest - INRA - UMR Pegase Domaine de la Prise 35590 Saint Gilles - France

Website www.biogenouest.org

Phone +33(0)6 76 23 53 22

Contact Jocelyne Le Seyec


Biogenouest is the Western France life science and environment core facility network. It brings together 34 technology core facilities that deliver hands-on solutions for labs and businesses across 6 technology areas within life and environmental sciences: Genomics, Proteomics, Functional exploration, Bioimaging, Structural and metabolic analysis and Bioinformatics. Research programmes are undertaken in the fields of Marine biology, Agriculture/Food-processing, and Human health.

BIOSIMS TECHNOLOGIES .................................J9 75 route de Lyons la Forêt, 76000 Rouen - France

Website www.biosims-technologies.com

Phone +33 (0)2 32 18 48 14

Contact Christine Heuclin


Quantification of low abundance proteins in body fluids represents a promising new field to explore. To this end, Biosims has combined protein microarrays with mass spectrometry. It enables a digital quantification with an unsurpassed sensitivity allowing it to quantify protein panels down to the fg/ml range. Biosims microarrays feature multiplex spots of sandwich immunoassays, where detection antibodies are quantified using one discrete mass-tag, thus needing no fluorescence

36

BOOST4HEALTH ..................................................... E2 310 avenue Eugène Avinée 59120 Lille - France

Website www.nweurope.eu/projects/project-search/boost4health-the-life-sciences-hub-of-nwe-b4h

Phone +33 (0)3 28 55 90 60

Contact Nicolas LABADIE


Boost4Health is an international programme that will help to accelerate international growth for innovative life science SMEs and clear a path for similar SMEs in the future. The vibrant transnational community Boost4Health will change the perspective on internationalisation for SMEs. Sharing insights, knowledge and contacts will transform the uncertainties and risks perceived with internationalization into tangible business opportunities for SMEs.

CELLVAX SAS..................................................... B7 102, Avenue Gaston Roussel 93230 Romainville - France

Website www.cellvax-pharma.com

Phone +33 (0) 9 52 30 26 20

Contact Mingxing Wei


Cellvax, founded in 2001, is a French SME which provides complete preclinical innovating drug validation studies both in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer, Osteoarthritis (OA) and anti-aging fields. Cellvax was created by a motivated and complementary team consisting of scientists and experts in these fields. By offering its know-how and its capacity of innovation.

CITOXLAB AND ATLANBIO .............................J5 BP 563 27005 EVREUX Cedex - France

Website www.citoxlab.com

Phone +33 (0)6 70 64 61 88

Contact Alexandre Chevallier


CiToxLAB is a key CRO player in Non-clinical drug development services. CiToxLAB offers a comprehensive range of non-clinical services to meet the needs of pharmaceutical, biotechnology, chemical, agrochemical and cosmetics companies worldwide. CiToxLAB core activities are in general and reproductive toxicology, carcinogenicity, immunology, safety pharmacology, DMPK, preclinical and clinical bioanalysis, as well as biomarkers and immunomonitoring through its main facilities and Atlanbio.

CZECHINVEST ...................................................D6 Stepanska15 12000 Prague - Czech Republic

Website www.czechinvest.org

Phone +420-724563229

Contact Hana Chlebna


CzechInvest, the investment and business development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages overseas companies to look at the Czech Republic as their location of choice. The agency helps its Czech and international customers by providing services that range from information provision and consultancy to implementation of business development programmes.

37

DELPHARM BIOTECH .......................................... H6 2, rue Alexander Fleming, CS 30612 69366 Lyon cedex 07 - France

Website www.delpharm.com

Phone +32 (0)6 30 31 14 05

Contact Jean-Frederic Loubereau


Delpharm Biotech is a CMO based in France, specialized in immuno diagnostics, DM-DIV and companion tests. Delpharm has no product catalogue and exclusively manufactures Immuno diagnostics on behalf of his customers Delpharm Biotech is focused in industrialization and manufacturing of rapid diagnostic tests (Lateral flow immuno Assays) and ELISA. Focused diagnostics markets: human AND veterinary diagnostic markets.

DRUGABILIS ..............................................................J9 5, rue JB Clement 92290 Chatenay-Malabry -France

Website www.drugabilis.com

Phone +32 (0)6 86 48 88 56

Contact Joel Vacus


Drugabilis research capabilities aim at fast selecting NCEs of high drugability. We characterize the phys-chem profiles of research compounds and APIs, design early formulations for animal studies (PoC, PK and tox studies), optimize API crystal forms (salts and polymorphism). We perform trouble-shooting studies to address development issues. Working with Drugabilis offers access to a unique experience of the discovery / development interface after more than 160 clients supported since 2004.

EGID .............................................................................. H9 (EUROPEAN GENOMIC INSTITUTE FOR DIABETES) Bd du Professeur Jules Leclercq, 59045 Lille -France

Website www.egid.fr

Phone +33(0)6 58 96 77 39

Contact Laurence Cellier


Created in 2009, Egid is the first research Institute dedicated to the study of diabetes, obesity and their complications. Egid was formed as a result of the combined knowledge and expertise of the 3 co-founders: • Pr. P. FROGUEL • Pr. B. STAELS • Pr. F. PATTOU The main mission of Egid is to identify diabetes’ risk factors, to understand the mechanisms of the development of their complications to prevent the onset of this crippling disease and better treat the patients.

ERDYN ........................................................................G9 23 RUE VERGNIAUD 75013 PARIS - France

Website www.erdyn.com

Phone +33 (0)1 77 75 79 81

Contact Kathye Sejourne


Erdyn is a leader consulting company specialized in innovation which aims to sustain growth and competitiveness through innovation. We help our customers in the health and biotech domain take the right decisions in their innovation projects and in their business development.

We offer:

- technological and scientific expertise for technology scouting, state of the art,...

- innovation marketing and business development consulting

- collaborative projects set up and management

38

EU-JAPAN ..........................................................F8 Rue Marie de Bourgogne, 52 1000 Bruxelles - Belgium

Website www.eu-japan.eu

Phone +32 (0) 22820040

Contact Eivilte Kandrataviciute


The EU-Japan Centre for Industrial Cooperation is seeking to identify EU clusters and SMEs interested in starting and/or expanding their activities with/in Japan in order to present to them European Commission-funded support services.

•Cluster/SME missions to Japan (ICT, Bio, Nanotech)

•Partnering support to identify potential partners in Japan (www.een-japan.eu)

•Help/Information desk (www.eubusinessinjapan.eu)

• Logistical support in Tokyo

ERAS INGÉNIERIE ............................................ B8 1 Route de Socx 59380 Bierne - France

Website www.eras.com

Phone +33 (0)6 87 29 26 90

Contact Patrick Fievet


ERAS is a multi-speciality engineering company dedicated to the process industries. We offer our clients services designed to improve the performance of their production sites and the management of their industrial investments, from project feasibility study through to commissioning of facilities. Long-term partner for major industrial groups: framework contracts and agreements represent 33% of our sales

EURASANTE ....................................................... B8 310 avenue Eugène Avinée 59120, Loos - France

Website lille.eurasante.com

Phone +33 (0)3 25 55 90 60

Contact Mathieu Evrard


Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector. Eurasanté works to promote the growth of the biology, health and nutrition sectors in the Hauts-de-France region. Our experienced project managers help researchers, startups and companies with their development projets. Eurasanté also promotes the Eurasanté Bio Business Park, located at the heart of a Leading public research centre (CHRU Lille), hosting 7 hospitals, 4 universities, 1 engineering and business school and more than 160 companies. It benefits from an exceptional location in the heart of Europe (near to Paris, London, Brussels…)

EUROFINS PHARMA DISCOVERY SERVICES ......................................H12 Le Bois L’Evêque 86600 Celle L’Evescault - France

Website www.eurofins.com/PharmaDiscovery

Phone +33 (0)5 49 89 30 00

Contact Jenny Thouvenin


For over 40 years, Eurofins Pharma Discovery Services has been a trusted CRO supporting drug discovery from HTS to preclinical stages. Uniting the expertise of Cerep, Panlabs & Discovery Services, we support efficacy, safety & PK testing with our products and in vitro pharmacology, phenotypic, ADME-Tox and in vivo services.

39

EUROFINS BIOPHARMA PRODUCT TESTING ...................................................................... H4 9 avenue de Laponie 91978 Courtaboeuf - Cedex France

Website www.eurofins.com/pharma-services/biopharma-product-testing.aspx

Contact Nathalie Som

Phone +33 (0)6 48 04 06 02


Eurofins Product Testing Biopharma, under pharmaceutical Accreditation, offers analytical services in GMP environment : Development, validation or transfer of methods, Chemical and biochemical analyzes, Microbiology, Biosafety and biological activity testing, Preparation and storage of cell banks, Import and release of clinical batches, Storage of samples from -180 ° C to 70 ° C, with cyclic and photostability conditions, Tailor-made secondary packaging, labeling and randomization clinic.

EUROSCREEN FAST .............................................. H3 47 Rue Adrienne Bolland 6041 Gosselies - Belgium

Website www.euroscreenfast.com

Phone +32 71 348 508

Contact Laurent Meeus


Euroscreen FAST, a business unit of Ogeda, provides a unique access to GPCR assay services with more than 20 years of expertise in the field and a state-of-the-art screening platform. We provide the largest catalogue on the market for these targets with over 820 functional and radioligand binding GPCR assays that can be used for high throughput screening, molecular pharmacology and profiling, as well as tailor-made assay development.

E-ZYVEC .............................................................. B8 Phone +33(0)6 11 92 34 96

Contact Sylvain Julien


R&D biologists use thousands of DNA vectors every month. We are offering an unprecedented easiness to create tailor-made vectors. Using a proprietary assembly technology we can accurately assemble DNA bricks in a single-step reaction. Our technology allows complete freedom in designing vectors. Our streamlined process ensures high-throughput –cheap- production. Try us to find out how e-Zyvec-tors can be!

GENECODE ................................................................ D1 Ahtri 8 10151 Tallinn - Estonia

Website www.genecode.com

Phone 3725045081

Contact Janika Leoste


GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing novel disease modifying drugs. Our overall ambition is to develop neuroprotective and potentially neurorestorative treatment which is –as yet- unavailable. With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. Our scientific partners are all internationally well known leading scientists.

GENOSCREEN ..........................................................B8 1,rue du professeur Calmette 59000 Lille - France

website www.genoscreen.fr/en

Phone +33 (0)3 20 87 73 35

Contact Stanley Germany


GenoScreen is a French biotech company. Since 2001 GenoScreen offers innovative services and solutions that help public and private sector research groups to characterize and exploit DNA. GenoScreen works on all kinds of genomes and proposes cutting-edge technologies. Our innovation strategy has generated a stream of successful projects, including top-level expertise in the characterization of microorganisms. GenoScreen’s research programs develop new applications in highly competitive fields.

40

HISTALIM .....................................................................J9 126 rue Emile Baudot, 34000 Montpellier - France

Website www.histalim.com

Phone +33(0)4 11 91 97 26

Contact Nicolas Mattei


Histalim, the European leading company in the field of histopathology, have been providing for ten years R&D services in histology, IHC, ISH and morphometry to pharmas and biotech companies. The company is particularly engaged in the areas of Immuno-Oncology, Therapeutic Antibodies, Companion Diagnostics, Implantable Medical Devices,… The GLP compliant facilities can perform regulatory preclinical tests, experimental assays and histopathology diagnostics in the framework of clinical trials.

ID2SANTÉ .................................................................. D7 2 avenue du Pr Léon Bernard CS 34317 35043 Rennes Cedex - France

Website www.id2sante.fr

Phone +33 (0)2 23 23 47 72

Contact Hélène Le Pocher


ID2Santé supports innovation in the health sector in Bretagne (French region). We link up key players in research, healthcare and business to develop innovative projects. We provide support from the concept through to the end product approved for health market. We promote the health sector’s expertise. ID2Santé is also the representative of the Atlanpole Biotherapies cluster in Bretagne. Expertises: medical technologies, e-health, biotechnologies pharma, nutrition, environment & health.

IDBS ...................................................................... C5 2 Occam Court, Surrey Research Park GU2 7QB, Guildford - United Kingdom

Website www.idbs.com

Phone 441 483 595 000

Contact Sarah Burgess


From pharmaceuticals to energy, healthcare to consumer goods, IDBS helps research and development (R&D) teams make discoveries that have the potential to transform the lives of populations worldwide. We are passionate about optimizing scientific process and making data genuinely useful and actionable. As a leading global provider of advanced software for R&D, we provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data.

IMMUNE INSIGHT .......................................... B8 1 rue du Professeur Calmette 59021, Lille - France

Website www.immune-insight.com

Phone +33 (0)3 20 87 11 27

Contact Hamza Aboussemdai


Immune insighT is a CRO which emerged from academic research. We are specialized in ex-vivo and in-vivo preclinical assessment of new active molecules on the immune system in the fields of Cancer, Autoimmune and Inflammatory diseases, Transplantation but also Agrofood and Cosmetic products. Having based on the features demanded by Big Pharma as well as small-cap drug development companies, we have created innovative essays to prevent a failure related especially to regulatory T cells (Tregs).

41

IMODE .......................................................................... E2 310 avenue Eugène Avinée 59120 Loos - France

Website www.eurasante.com

Phone +33 (0)3 28 55 90 60

Contact Caroline Simoes-Auberger


IMODE is a collaborative transdisciplinary research and development program financed by Interreg. This program is on multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices loaded with bioactive molecules. It aims at providing novel and effective solutions for various gastrointestinal and cardiovascular diseases that will improve patients quality of life.

INPI ...............................................................................G3 97 boulevard Carnot 59040 Lille Cedex - France

Website www.inpi.fr

Phone +33 (0)3 28 36 33 81

Contact Didier Darguesse


The French Industrial Property Office (INPI) grants patents, registers trademarks and designs, and provides comprehensive information on industrial property and companies. It actively takes part in formulating and implementing public policies as regards industrial property and the fight against counterfeiting. Thanks to the development of its range Coaching INPI, it also supports companies (TPE, SME, Mid-Caps, Start-up) in their strategy of innovation and industrial property.

ITEC SERVICES ...........................................................J9 3 avenue Georges Clemenceau 33150 Cenon - France

Website www.itecservices.com

Phone +33 5 57 77 85 00

Contact Mathieu Caperra


Since 1984, a France based CRO, privately owned and medically driven. The main objective of ITEC Services is to conduct national and worldwide clinical trials and post authorisation studies for pharmaceutical, biotechnological and medical device companies.

- Strategic and development advice

- Regulatory services

- Clinical operations : Pilot, Phase I, II, III, IV studies

- Epidemiology and Late phase

- Biometry

- Drug safety

- Quality assurance

KIC EUROPE ........................................................F7 Rue de la science 14A 1040 Bruxelles - Belgium

Website kiceurope.eu

Phone +32(0)2 880 3905

Contact Heewon Shim


KIC-Europe is the first Research & Innovation Centre in Brussels to develop an integrated cooperation and to build a large network in research and innovation between Korea and the EU, opening opportunities for Korean startups and SMEs to expand into European markets by providing strategic solutions and networking. Our aims are to help government-funded research institutes, Korean universities and other organisations in order to encourage participation in international joint research projects

42

LIFE & SOFT ................................................................. I6 Les Colocs (Parc Novéos), 8b Avenue Descartes 92350 Le Plessis-Robinson - France

Website www.lifeandsoft.com

Phone +33 (0)6 19 53 89 27

Contact Eric Ginoux


Our IT and Research teams offer their expertise in bioinformatics, biostatistics and biology to make Life&Soft your key partner to reach your Research and Diagnosis goals in Health Sciences. We are building bioinformatics pipelines to perform Next Generation Sequencing analysis. Our innovative applications provide valuable, accurate and high quality results from biological samples. Our consulting IT services will help you improve your scientific computing and let you focus on your Research.

MEDICEN PARIS REGION ..................................C2 Medicen Paris Region 75014 PARIS - France

Website www.medicen.org

Phone +33 (0)1 79 68 10 89

Contact Alexia Decarme


Founded in 2005, the Medicen Paris Region global competitiveness cluster aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine.

MINNETRONIX ..................................................... H5 1635 Energy Park Drive 55108 St. Paul - USA

Website www.minnetronix.com

Phone +1 651 917 4060

Contact Jackie Freppert


Minnetronix is a medical technology and innovation company with deep expertise in electronic and electromechanical devices. Founded in 1996, in St. Paul, Minnesota, USA, the company creates new technologies and therapies that solve unmet clinical and business needs for patients and medical device companies. Minnetronix leverages its broad industry knowledge to provide innovative and strategic partnership options, as well as design, development, and manufacturing services. The company offers multiple pathways to create value, including intellectual property generation and new business models. Minnetronix is FDA Registered and ISO 13485 Certified.

MYCARTIS ................................................................G11 Technologiepark 49 052 Zwijnaarde - Netherlands

Website www.mycartis.net

Phone +31 (0)6 29 33 11 22

Contact Ronald Vos


Biomarker analysis designed to make healthcare personal.MyCartis delivers innovative detection system for fast and cost effective identification of patient’s specific biomarkers signatures in order to provide precise and personalized health decisions.

We operate at the forefront of biomarker analysis by offering the next generation biomarker analysis platform. At MyCartis we collaborate to innovate.

43

NUTRITION HEALTH LONGEVITY CLUSTER .............................................................. B8 310 avenue Eugène Avinée 59120 Loos - France

Website www.nhl-cluster.com

Phone +33 (0)3 25 55 50 14

Contact Alexandre Labe


The NHL Cluster is the only French cluster to combine Nutrition, Biotechnology and Health. The NHL Cluster focuses on the fields of prevention and treatment of life-style related diseases. We identify opportunities (technology, market, product, financial aid), we facilitate exchange between potential and existing members, we contribute to collaborative R&D projects between academia, national and international public research institutions and private companies.

OCR ............................................................................... D5 80, rue du Dr Yersin 59120 Loos - France

Website www.oncovet-clinical-research.com

Phone +33 (0)6 63 51 39 71

Contact Matthieu Dubruque


OCR is focused on comparative medicine studies of dogs with spontaneous cancers and chronic diseases, as natural animal models for assessment of drug candidates under development for Human. OCR provides to Biotech-Pharma-MedTech companies more predictive data of human diseases for a more relevant development in clinic. OCR also acts as a full vet-CRO for pilot and pivotal studies for the Vet market. OCR benefits from an internal histology/IHC platform and a canine and feline tumor biobank

ONCOLILLE ........................................................G8 6, rue du Professeur Laguesse 59037 Lille Cedex France

Website www.oncolille.fr

Phone +33 (0)3 20 44 63 46

Contact Maximilien Vanleene


Selected by the French Cancer National Institute (INCa), ONCOLille is a consortium of researchers and clinicians of the Lille Metropolis working together in oncology, cell and molecular biology, imaging, biostatistics and human & social sciences, to promote a swift interaction between basic and clinical researches for the direct patient benefit. ONCOLille address two crucial issues of modern oncology: Tumor resistance to loco regional therapies and tumor dormancy and persistence.

ORIGINAL PROCESS ...........................................B8 21 rue Saint André 59000 Lille - France

Website www.original-process.com

Phone + 33 (0)3 20 21 88 90

Contact Isabelle Delporte


Original Process, specialist of the health of digestive microbiotia of animals for 40 years. From its exclusive technology of fermentation of cereals, called FAP ®, Original Process developed exclusive Processes ending in the elaboration of a range of products: the ProbioactiFAP ®. Naturally rich in prebiotic and postbiotic bioactive molecules, they stimulate firstly certain beneficial microorganisms and their activities to the detriment of the pathogenic, throughout the digestive tract.

44

OROXCELL ...................................................................J9 102 avenue Gaston Roussel 93230 Romainville - France

Website www.oroxcell.com

Phone +33 (0)1 41 83 72 22

Contact Christophe Dini


For more than a decade Oroxcell has strived to offer industry-leading ADME/Tox services that provide physiologically relevant results, from screening to GLP compliant studies. Our clients and partners include Pharma, Dermo-Cosmetic, Home & Care products, Medical Device, and Chemical Industries. Additionally, Oroxcell holds a R&D program for pain treatment.

PHARMA LOGISTICS CLUB(PLC) ................... F6 7, rue Castellane 75008 Paris - France

Website www.pharmalogistics.club

Phone +33 (0)6 44 15 30 83

Contact Serge Alezier


The Pharma Logistics Club (PLC) is a non-profit inter-professional association, to intellectual vocation, managed by professionals belonging to health establishments and providers from all sectors, without distinction of specialties in the field of Supply Chain Pharmaceutical. Its purpose is to bring together people interested in participating to a better understanding and improvement of GDP. International positioning, we offer conferences, technical committees, logistics site visits and online tools.

POLEPHARMA .................................................D7 11 rue du Cardinal Pie 28000,Chartres - France

Website www.polepharma.com

Phone +33 (0)2 47 36 63 41

Contact Sophie Ehrhardt


The role of Polepharma is to stimulate the industrial and economic development of the companies involved in the first pharmaceutical industrial cluster in France, through actions promoting Competitiveness, Innovation and the vitality of our Network. Missions :- Favoring a joint industrial culture, gathering together academic research and industry to create social-economic value on the territory of Polepharma; - Accelerating the collaborations between academic research and industry specially in the biopharmaceutical fields

PORSOLT .............................................................J9 ZA de Glatigné 53940 Le Genest Saint-Isle - France

Website www.porsolt.com

Phone +33 (0)2 43 69 36 07

Contact Sébastien Breche


Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiples species and multiple disease areas, tailored solutions and bespoke model development.

45

PRECIGENICS .................................................... B8 Phone +33 (0)3 20 97 42 62

Contact Hafid Mezdour


Precigenics is a Spin-Off of UMR-8199 CNRS laboratory and Ligan-MP, an NGS platform. Precigenics has developed an innovative precision diagnostic solution that integrates genomics and metabolomics, complemented by expert analysis of data and interpretation. Precigenics target priorities are chronic diseases including diabetes, cardiovascular, and cancer. Precigenics mission is to improve health by providing clinicians useful information to prevent, diagnose, and treat disease and conditions.

PULSALYS SATT LYON ST-ETIENNE ...........I12 47 bd du 11 novembre 1918 69625 Villeurbanne - France

Website www.pulsalys.fr

Phone +33 (0)6 03 26 49 84

Contact Daphné Thomas


PULSALYS is a technology transfer office, created within the framework of the Future Investment Programme initiative, working on Lyon Saint-Etienne territory. Privileged actor of the innovation economic development, PULSALYS aims to promote academic research throught technologies transfer from labs University of Lyon to socio economic markets. In order to this, PULSALYS sells innovate products/services to companies or assists research team to business bulding

RD-BIOTECH ...............................................................J9 3, rue Henri Baigue 25000 Besançon - France

Website www.rd-biotech.com

Phone +33 (0)7 86 81 41 38

Contact Sylvie Mercier


RD-Biotech is a French CRO that proposed services in biotechnology: Bioproduction: mAb, recombinant proteins, plasmids Research contracts: cell line, hybridoma development, cloning, humanization, ELISA @Biotech Investissement, majority shareholder of RD-BIOTECH, acquired Diaclone SAS on 2012: a wide range of mAbs & Immunoassays SynAbs, a Belgium company. Joined the Group last month. Its expertise in rat mAb greatly complement the expertise of the sister companies in the field of mAbs

RÉSEAU SATT ..........................................................I12 c/o IDF Innov, 37 rue de Lyon 75012 Paris - France

Website www.satt.fr

Phone +33 (0)3 59 01 68 88

Contact Rémi Lefebvre


In France, SATTs have the challenging mission to accelerate the transformation of French research into innovations. Their aim is to enhance the value and to accelerate the process of technology transfer from publically funded research toward industry. SATTs evaluate, market and license technology from French Universities and Public Research Organisations. SATTs have become a major actor of economic development to reinforce company competitiveness, with an emphasis on SMEs and start-ups.

46

SATT AXLR ...............................................................I12 950 rue Saint-Priest - CSU Bâtiment 6 34090, Montpellier - France

Website www.axlr.com

Phone +33 (0)4 48 19 30 01

Contact Hervé Ansanay


AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France’s Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

SATT CONECTUS ALSACE ............................I12 650 Bd Gonthier d’Andernach 67400 Illkirch - France

Website www.conectus.fr

Phone +33 (0)3 68 41 12 79

Contact Emilie Denat


SATT Conectus Alsace is the single entry point for companies and exclusive business partner to access to all the innovations originating from public research institutions in Alsace, one of the top ranked regions in France for the excellence of research. It is also the partner of choice to access a unique and broad range of highly advanced knowhows, skills and facillities, within a favourable geographic position in the heart of Europe (Alsace borders Germany and Switzerland).

SATT GRAND CENTRE ........................................I12 8, rue Pablo Picasso 63000 Clermont-Ferrand - France

Website www.sattgc.com

Phone +33 (0)4 73 60 18 30

Contact Marjorie Boularand


SATT Technology Transfer Organisation (Center of France) organises early detection of inventions and guarantees its exclusivity. SATT Center of France reveals the potential of future innovations for a successful transfer to business in providing financial and technical supports. Located in Clermont-Ferand, SATT Center of France works with 7 Universities, 4 Régions, 7 Institutes of Technology and 8500 Researchers and Professors.

SATT IDF INNOV .............................................I12 37 rue de Lyon, 75012 Paris - France

Website www.idfinnov.com

Phone + 33 (0)1 44 23 21 50

Contact Marie-Christine Servant


IDF Innov is a private TTO with exclusive rights on technology detection, seeding and commercialization over a vast academic territory in the Paris Metropolitan Area. This territory is strong of more than 17000 researchers, clinicians and PhDs, and hosts the strongest cluster for clinical expertise in France. IDF Innov operates as a seeding funds and is committed to facilitate the due diligences for IP related private-public partnering and start-up creation.

47

LINKSIUM ..........................................................I12 31 rue Gustave Eiffel 38000, Grenoble - France

Website www.linksium.fr

Phone +33(0)4 57 13 81 50

Contact Véronique Souverain


Linksium is a major player in technology transfer and startups building. Business players can easily scout most promising technologies coming from public research results. This unique combination of Tech Transfer & startups building stimulates success of innovation projects. Linksium carefully selects and funds projects with valuable intellectual property inside. All technologies are disruptive, protected and available for industry.

SATT LUTECH ....................................................I12 24 boulevard de l’hopital 75005 Paris - France

Website www.sattlutech.com

Phone +33 (0)1 78 94 68 51

Contact Jérémy Guillaume


Created as a part of the «Investissement d’Avenir» program, SATT Lutech is a private company specialized in technology transfers : this company detects, protects, develops and commercializes the skills and research results coming from its partner institutions. Its mission is to facilitate the emergence of innovations with a real economic and/or social potential. Lutech invests in the development of proof of concept and/or prototype to support innovative projects, from laboratory to market.

SATT NORD ......................................................I12 25 avenue charles st venant -Immeuble central gare 59000, Lille - France

Website www.sattnord.fr

Phone +33 (0)2 83 68 96 6

Contact Caroline Brillant


SATT Nord is a growth-generating tool for valorisation serving researchers and responding to the economic and societal needs for technology transfer.Thanks to a multidisciplinary team of professionals (experts in the various fields of research, project managers, experts in intellectual property, legal experts), SATT Nord ensures the detection of projects, their maturation and the protection of the intellectual rights and even up to their commercialisation through transfer.

SATT OUEST VALORISATION ......................I12 14C, rue du Patis Tatelin 35000, Rennes - France

Website www.ouest-valorisation.fr

Phone +33(0)6 18 70 35 04

Contact Hervé Le Deit


Ouest Valorisation – Office of Technology Transfer (OTT) was created in the “Future Investments” project call managed by Ministry of Higher Education and Research. Its aim: to propose to companies attractive innovation means from the public research. Ouest Valorisation’s team simplifies the access of the companies to research laboratories in order to develop good collaborative projects or to get access to high professional skills and high level scientifical equipment.

48

SATT PARIS-SACLAY ...........................................I12 86 rue de Paris 91400 ORSAY - France

Website www.satt-paris-saclay.fr

Phone +33 (0)1 84 00 00 31

Contact Lydwine Héneault


SATT Paris-Saclay was established in 2014 in Orsay, France, to help create value from research at Paris-Saclay University and support the transfer of new technologies and know-how to industry. With funding provided through the French government’s economic stimulus package (Investissements d’avenir), SATT Paris-Saclay is also tasked with leveraging innovation to spur local economic growth and job creation.

SATT SUD EST ...................................................I12 8 rue Sainte Barbe CS 10422 13205 Marseille Cedex 01 - France

Website www.sattse-technologies.com

Phone +33 (0)4 13 24 66 10

Contact Rémi Picard


SATT Sud Est helps companies to boost their competitiveness through innovation stemming from public research of South Eastern France.Its core business involves bringing inventions developed by its shareholder research bodies to readiness on intellectual property, market and proof of concept levels. SATT is focused on bridging the technology gap between these innovative technologies and their industrial-scale production and transferring them through granting operating licenses to companies.

SENCET ................................................................ B8 Phone +33 (0)6 61 18 57 01

Contact Grégoire Perret


The Sencet startup relies on the Silicon Nanotweezer (SNT) technology, developed since 10 years at CNRS. The concept relies on the use of microtechnologies to measure the electrical and mechanical properties of individual cells. This type of measurement has been shown to allow the differentiation of normal and cancer cells. In the short term, Sencet product will take place in a laboratory environment and in the middle term (5 years) in ambulatory environment as a diagnostic tools for cancer.

SIMV ............................................................................. D3 50, rue de Paradis 75010 PARIS - France

Website www.simv.org

Phone +33 (0)1 53 34 43 43

Contact Sonia Afonso


The SIMV represents Companies engaged in research, manufacturing and marketing of medicinal and diagnostic products, devices and animal health technologies. The SIMV contributes to their competitiveness by mobilizing one permanent team and 650 employees working in interaction. The ambition of the SIMV to Biofit 2016 is to work in favor of a European ecosystem supporting an open innovation in animal health.

LILLE NORTHERN FRANCE BIOINCUBATOR

49

LILLE NORTHERN FRANCE BIOINCUBATOR

SMALTIS ......................................................................J9 2 rue Paul Milleret 25000 Besançon - France

Website www.smaltis.fr

Phone +33 (0)6 07 91 91 72

Contact Cédric Muller


The SMALTIS compagny, specialized in biotechnologies, designs through contracted services, customized solutions in Microbiology

and Molecular Biology to help laboratories with their R&D projects. Its strengh relies on a qualified team with specific know-how and an ISO 9001 certification in order to provide a personalized, confidential, interactive and quality service. With a solid scientific background and a diversified and certified «toolbox», SMALTIS operates globally in R&D projects.

SOFISE .......................................................................G12 21 rue Pasteur 44119 Treillieres - France

Website www.sofise-filtration.com

Phone +33 (0)6 26 75 34 79

Contact Olivier Retiere


Since 2004, SOFISE is an active company in the world of Filtration -liquid and air-, from prefiltration to sterile filtration included endotoxins removals and in decontamination of surfaces and rooms. During this time, we worked on TFF applications and SOFISE has become the french distributor of QUATTROFLOW who created a large range of specific pumps for Biotech and Pharmaceutical applications with low shear, low pulsation, no cell damage, ...., with 2 configurations : Single-Use & Multiple-Use

SOLADIS .................................................................... D2 94 rue Saint Lazare 75009 Paris - France

Website www.soladis.fr

Phone +33 (0)6 07 26 22 69

Contact Anthony Perrussel


Soladis and its BU dedicated to clinical studies management Soladis Clinical Studies provide statistical and clinical services to Life Sciences actors (Pharma, MedDev, Biotech, Agro, Cosmetic) at any stage of the product life cycle: R&D, Preclinical & Clinical development, Production, and Marketing/PMS. Combining both Medical and Statistical expertise working in an efficient synergy, Soladis CS, highly experienced full-service CRO, carries out your studies from protocol to report or publication.

TOULOUSE TECH TRANSFER........................I12 MRV - 118 route de Narbonne 31432 Toulouse - France

Website www.toulouse-tech-transfer.com

Phone +33 (0)5 62 25 50 60

Contact Claire Metais


Following a French National initiative, 14 technology transfer companies called SATTs have been created to boost the technology transfer. Toulouse Tech Transfer was created in January 2012 as one of the first five SATTs. TTT’s core business is to invest in technology maturing programs (proofs of concept) based on academic research results of the Midi-Pyrénées region. The objective of these investments is to license the matured technologies and products to businesses.

50

VALBIOTIS ..................................................................B8 40 rue Chef de Baie 17000 La Rochelle - France

Website www.valbiotis.com

Phone +33 (0)6 63 78 81 70

Contact Philippe Charier


VALBIOTIS is a biopharmaceutical company distinguished by its unique approach to chronic metabolic disorders. Its proprietary R&D platform discovers and develops first-in-class patented polymolecular complexes indicated at specific stages in the progression of chronic illnesses such as type-2 diabetes, obesity, dyslipidemia or even NASH (Non-Alcoholic Steatotic Hepatitis). From the plant to the polymolecular complex, and from prevention to treatment, dedicated to people’s health and well-being.

VAXINANO ....................................................... B8Website www.vaxinano.com

Phone + (0)33 (0)6 75 42 26 00

Contact Vincent Lemonnier


Vaxinano is a technological patented platform relying on nanoparticles used as delivery systems. The first field of application is vaccination, for both human and veterinary markets. We propose more stable and more efficient “ready to market” vaccines based on biocompatible nanoparticles made of starch and lipids. Our vaccines are designed for the easy and non-intrusive nasal route. This platform can be used for a wide set of applications to treat viral, bacterial and parasitic infections.

VIALTO ......................................................................... F5 40 rue saint jean de Dieu 69366 lyon cedex 07 - France

Website www.stars-service.com/transport-produits

Phone +33 (0)6 75 61 98 52

Contact Nicolas Pasquier


Vialto, the Expert in transportation of sensitive Health products. The insurance of a secured shipping compliant with all Regulatories requirements.Combining reliability and expertise, vialto is the 1st French carrier to be certified ISO 9001 v2015 by Dekra. Vialto offers a large range of facilities dedicated to sensitive and fragile medical products transport under controlled temperatures.

X’PROCHEM ..................................................... B8 Website www.xprochem.fr

Phone +33 (0)6 18 76 48 70

Contact Reda Mhidia


X’PROCHEM provides proteins manufactured through an innovative chemical process. Risks, costs and times of your APIs-development can be reduced by 40% regarding biological processes of production. Our services of custom proteins synthesis (e.g. glycosylation, PEGylation) can help you to improve pharmaceutical properties of your products and reach their full potential. X’PROCHEM opens new possibilities to rationalize the construction of your innovative proteins with the required purity and scale.

51

People are different and so are diseases. That’s why we are committed

to discovering and developing personalised medicines and targeted diagnostic tests to help people live better, longer lives.

APPROACHING ONCOLOGY FROM A DIFFERENT DIMENSIONIpsen has a strong heritage in oncology. Success is comprised of experience, vision and passion.

Like a master watchmaker, we are focused on innovation and precision for new therapeutic options in oncology.

We remain committed to developing effective and innovative therapeutic solutions to improve treatment outcomes for patients and to support healthcare professionals in their daily practice. TA I L O R E D O N C O L O G Y

52

7 OFF ICES IN EUROPE

Paris • Lille • Lyon • Marseille

Munich • Duisburg • Birmingham

CONTAC T US

Phone: +33 1 44 18 89 00

Fax: +33 1 44 18 04 23

[email protected]

FOLLOW US

www.bdl-ip.com

Cabinet Beau de Loménie

@BDL_IP

Pan european IP firm Cabinet Beau de Loménie has over 200 professionals including 70 engineers, lawyers and IP attorneys with strong experiences in all technical domains and industry sectors, including pharmacy and biotechnology. Our experts help creative companies from start-up toestablished businesses, to secure their groundbreaking ideas and exploit them throughout theworld. Cabinet Beau de Loménie provides global and custom-made solutions for obtaining,optimizing and defending your intellectual property rights (patents, designs, trademarks, domain names).

experts with creative mindsIP

flexible

prevent complications

treatment options

patient focus

more freedomquality of life

self-management

overcoming barriers

empowered

healthy

For over 90 years, we have been helping people with diabetes to live with fewer

limitations. We will continue to discover and develop treatments that meet

individual needs as we work towards our ultimate goal – defeating diabetes.

innovating for better

diabetes care

Learn more about our innovations at novonordisk.com/rnd

Changing D

iabetes® and the A

pis bull logo are registered trademarks of N

ovo Nordisk A

/S. HQ

MM

A/C

D/0416/0267a

13264_ACDC_Posters_A1_Landscape_D.indd 1 10/05/16 10:00

53 Phot

o cr

edit

; Je

an M

iche

l And

ré

BioParty30th November from 7.00 pm

CCI Grand Lille

Live entertainment

LILLE

A shuttle service is available from Lille Grand Palais to the CCI Grand Lille.

Departure times:6.30 pm • 6.45 pm • 7.00 pm • 7.15 pm

Pick-up area: In front of Lille Grand Palais main entrance

Transport and access

Place du théâtre - 59000 Lille

flexible

prevent complications

treatment options

patient focus

more freedomquality of life

self-management

overcoming barriers

empowered

healthy

For over 90 years, we have been helping people with diabetes to live with fewer

limitations. We will continue to discover and develop treatments that meet

individual needs as we work towards our ultimate goal – defeating diabetes.

innovating for better

diabetes care

Learn more about our innovations at novonordisk.com/rnd

Changing D

iabetes® and the A

pis bull logo are registered trademarks of N

ovo Nordisk A

/S. HQ

MM

A/C

D/0416/0267a

13264_ACDC_Posters_A1_Landscape_D.indd 1 10/05/16 10:00

54

NOTES................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

................................................................................................................................................

By 2050 the world’s population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society.That’s why we’re seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions,

solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn’t stop at 60 – not by any means.To find out how our innovations are helping to change lives for the better, visit www.bayer.com/ari1901.

FOR MANY, AN ACTIVE LIFESTOPS FAR TOO EARLY

OUR SCIENTISTSWON’T ACCEPT THAT

Corporate_Ad_EN_Pharma_A5.indd 1 15/11/2016 16:10

55

THEY SUPPORT US

SILVER SPONSORS BRONZE SPONSORS

GOLD SPONSORS

CONTRIBUTING SPONSORS

MAIN SUPPORTERS

MEDIA PARTNERS

SUPPORTERS

Cabinet Beau de Loménie

By 2050 the world’s population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society.That’s why we’re seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions,

solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn’t stop at 60 – not by any means.To find out how our innovations are helping to change lives for the better, visit www.bayer.com/ari1901.

FOR MANY, AN ACTIVE LIFESTOPS FAR TOO EARLY

OUR SCIENTISTSWON’T ACCEPT THAT

Corporate_Ad_EN_Pharma_A5.indd 1 15/11/2016 16:10

56

A 360° approach to source early stage innovations in Life Sciences

th edition 30 nov & 1 dec 2016 - biofit 2020 › programme final bf2016_web.pdfpartnering events...

Documents